Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …

Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell
haematologic malignancies. The manufacturing of these T cells typically involves their …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

Natural killer (NK) cells, a subgroup of innate lymphoid cells, act as the first line of defense
against cancer. Although some evidence shows that NK cells can develop in secondary …

Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …